Market Snapshot
S&P Futures
3,914.75
Dow Futures
31,478
Nasdaq Futures
12,132.75
Athira Pharma, Inc. (ATHA) stock declined over -3.51% intraday to trade at $2.75 a share on NASDAQ. The stock opened with a gain of 4.17% at $2.82 and touched an intraday high of $2.83, falling -3.51% against the last close of $2.85. The stock went to a low of $2.58 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-23 | $2.82 | $2.83 | $2.58 | $2.75 | 4,788,800 |
2022-06-22 | $2.64 | $3.1 | $2.53 | $2.85 | 22,040,900 |
2022-06-21 | $8.74 | $8.9 | $8.41 | $8.45 | 355,000 |
2022-06-17 | $8.28 | $8.998 | $8.13 | $8.6 | 431,700 |
2022-06-16 | $8.04 | $8.244 | $7.9 | $8.1 | 221,800 |
2022-06-15 | $8.09 | $8.42 | $7.96 | $8.22 | 167,700 |
2022-06-14 | $8 | $8.09 | $7.84 | $8.03 | 141,400 |
2022-06-13 | $7.95 | $8.24 | $7.81 | $8.05 | 250,900 |
2022-06-10 | $8.11 | $8.22 | $7.95 | $8.16 | 170,000 |
2022-06-09 | $9 | $9 | $8.35 | $8.36 | 157,800 |
Employees-
Beta-
Sales or Revenue0
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryPharmaceuticals
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Athira Pharma, Inc. (NASDAQ: ATHA) stock price is $2.75 as of the last check on Thursday, June 23. During the trading session, ATHA stock reached the peak price of $2.83 while $2.58 was the lowest point it dropped to.
The NASDAQ listed ATHA is part of Pharmaceuticals industry that operates in the broader Health Care sector. Athira Pharma, Inc. , a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation.
Dr. Mark J. Litton M.B.A., MBA, Ph.D.
Pres, CEO & Director
Ms. Rachel P. Lenington M.B.A.
Chief Operating Officer
Mr. Mark F. Worthington J.D.
Gen. Counsel & Corp. Sec.
Ms. Glenna K. Mileson
Chief Financial Officer
ATHA stock traded closed the last session at $2.75, which is $-0.10 or -3.51% lower than its previous close of $2.85. ATHA's current trading price is 8.70% lower than its 52-week high of $16.65 where as its distance from 52-week low of 2.53% is -83.48%.
Number of ATHA employees currently stands at -. ATHA operates from 18706 North Creek Parkway, Suite 104, Bothell, WA 98011, United States.
Official Webiste of $ATHA is: https://www.athira.com
ATHA could be contacted at ATHA operates from 18706 North Creek Parkway, Suite 104, Bothell, WA 98011, United States, or at phone #425 620 8501 and can also be accessed through its website.
ATHA stock volume for the day was 4,787,184 shares while in the previous session number of ATHA shares traded was 4,788,800 . The average number of ATHA shares traded daily for last 3 months was 639.73 Thousands.
The percentage change in ATHA stock occurred in the recent session was -3.51% while the dollar amount for the price change in ATHA stock was $-0.10.
In the recent session, the day high for ATHA stock was $2.83 while the low for ATHA stock touched on the day was $2.58.
The market value of ATHA currently stands at 97.49 Million with its latest stock price at $2.75 and 37.59 Million of its shares outstanding.